Rules of evidence for cancer molecular-marker discovery and validation

Nature Reviews Cancer

Volumn 4, Issue 4, 2004, Pages 309-314

  Ransohoff, David F ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER RESEARCH; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA MICROARRAY; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENOMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

EID: 1942438016     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1322     Document Type: Review

References (58)

1. Ramaswamy, S. & Perou, C. M. DNA microarrays in breast cancer: the promise of personalised medicine. Lancet 361, 1576-1577 (2003).
2. Kolata, G. Breast cancer: genes are tied to death rates. New York Times A1 (December 19, 2002).
3. Zhu, W. et al. Detection of cancer-specific markers amid massive mass spectral data. Proc. Natl Acad. Sci. USA 100, 14666-14671 (2003).
4. US Preventive Services Task Force. Guide to clinical preventive services 2nd edn Ch. 2 (US Government Printing Office, 1996).
5. Woolf, S. H. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Arch. Intern. Med. 152, 946-952 (1992).
6. Tannock, I. F. & Warr, D. G. Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ 159, 801-802 (1998).
7. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl J. Med. 319, 525-532 (1988).
8. Ahlquist, D. A. et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219-1227 (2000).
9. Stears, R. L., Martinsky, T. & Schena, M. Trends in microarray analysis. Nature Med. 9, 140-145 (2003).
10. Ransohoff, D. F. Developing molecular biomarkers for cancer. Science 299, 1679-1680 (2003).
11. Thomson, D. M., Krupey, J., Freedman, S. O. & Gold, P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl Acad. Sci. USA 64, 161-167 (1969).
12. Reid, M. C., Lachs, M. S. & Feinstein, A. R. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 274, 645-651 (1995).
13. Ransohoff, D. F. & Feinstein, A. R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N. Engl. J. Med. 299, 926-930 (1978).
14. Sackett, D. L. Zlinkoff honor lecture: basic research, clinical research, clinical epidemiology, and general internal medicine. J. Gen. Intern. Med. 2, 40-47 (1987).
15. Feinstein, A. R. Clinical biostatistics XXXI. On the sensitivity, specificity, and discrimination of diagnostic tests. Clin. Pharmacol. Ther. 17, 104-116 (1975).
16. Ransohoff, D. F. Challenges and opportunities in evaluating diagnostic tests. J. Clin. Epid. 55, 1178-1182 (2002).
17. Sullivan Pepe, M. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001).
18. Sackett, D. L., Haynes, R. B., Tugwell, P. & Guyatt, G. H. Clinical Epidemiology: a Basic Science for Clinical Medicine (Little, Brown and Company, Boston, 1991).
19. Bogardus, S. T., Concato, J. & Feinstein, A. R. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 281, 1919-1926 (1999).
20. Deyo, R. A. & Jarvik, J. J. New diagnostic tests: breakthrough approaches or expensive add-ons? Ann. Intern. Med. 139, 950-951 (2003).
21. Simon, R. & Altman, D. G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69, 979-985 (1994).
22. Wasson, J. H., Sox, H. C., Neff, R. K. & Goldman, L. Clinical prediction rules. Applications and methodological standards. N. Engl. J. Med. 313, 793-799 (1985).
23. Lachs, M. S. et al. Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann. Intern. Med. 117, 135-140 (1992).
24. Jaeschke, R., Guyatt, G. & Sackett, D. L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271, 389-391 (1994).
25. Sackett, D. L. & Haynes, R. B. The architecture of diagnostic research. BMJ 324, 539-541 (2002).
26. Bossuyt, P. M. et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann. Intern. Med. 138, 40-44 (2003).
27. Bossuyt, P. M. et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med. 138, W1-W12 (2003).
28. Potter, J. D. At the interfaces of epidemiology, genetics and genomics. Nature Rev. Genet. 2, 142-147 (2001).
29. Ambroise, C. & McLachlan, G. J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc. Natl Acad. Sci. USA 99, 6562-6566 (2002).
30. Simon, R., Radmacher, M. D., Dobbin, K. & McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95, 14-18 (2003).
31. Katz, M. H. Multivariable analysis: a primer for readers of medical research. Ann. Intern. Med. 138, 644-650 (2003).
32. Selaru, F. M. et al. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 122, 606-613 (2002).
33. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
34. Qu, Y. et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48, 1835-1843 (2002).
35. Huang, E. et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596 (2003).
36. Harrell, F. E. Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, And Survival Analysis (Springer-Verlag, New York, 2001).
37. Ntzani, E. E. & Ioannidis, J. P. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362, 1439-1444 (2003).
38. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
39. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
40. Ransohoff, D. F. Gene-expression signatures in breast cancer. N. Engl. J. Med. 348, 1715-1717 (2003).
41. Baker, S. G., Kramer, B. S. & Srivastava, S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med. Res. Methodol. 2, 4 (2002).
42. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
43. Brenton, J. D. & Caldas, C. Predictive cancer genomics: what do we need? Lancet 362, 340-341 (2003).
44. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
45. Hunter, K. W. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett. 200, 97-105 (2003).
46. Masters, J. R. & Lakhani, S. R. How diagnosis with microarrays can help cancer patients. Nature 404, 921 (2000).
47. Pharmalicensing. Agenda to develop microarray-based breast cancer test using Agilent Technologies' gene expression platform [online], (cited 22 Sept. 2003) 〈http://atlas.pharmalicensing.com/news/headlines/1061 478551_3f44e0970c520〉 (2003).
48. Wooster, R. & Weber, B. L. Breast and ovarian cancer. N. Engl. J. Med. 348, 2339-2347 (2003).
49. Feinstein, A. R. Multivariable Analysis: An Introduction (Yale University Press, New Haven, 1996).
50. Fletcher, R. H., Fletcher, S. W. & Wagner, E. H. Clinical Epidemiology: The Essentials 3rd edn (Williams & Wilkins, Baltimore, 1996).
51. Bleeker, S. E. et al. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 56, 826-832 (2003).
52. Sorace, J. M. & Zhan, M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4, 24 (2003).
53. Baggerly, K. A., Morris, J. S. & Coombes, K. R. Reproducibility of SELDI-TOF protein patterns in serum: comparing data sets from different experiments. Bioinformatics. 29 Jan 2004. (doi: 10.1093/bioinformatics/btg484)
54. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
55. Feinstein, A. R. Clinical Epidemiology: The Architecture of Clinical Research (WB Saunders, Philadelphia, 1985).
56. Hennekens, C. H. & Buring, J. E. Epidemiology in Medicine (Little, Brown and Company, Boston, 1987).
57. Freiman, J. A., Chalmers, T. C., Smith, H. Jr & Kuebler, R. R. The importance of β, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 'negative' trials. N. Engl. J. Med. 299, 690-694 (1978).
58. Ransohoff, D. F. Discovery-based research and fishing. Gastroenterology 125, 290 (2003).